One of the leading market players in gastroparesis drugs industry, Evoke Pharma Inc., recently experienced a rise in short interest of 17.97% in shares. The company presented a report on October 13, 2017.
As per the statistics, short interest increased from 931,701 to 1,099,173. The short-interest ration reached at 6.0 as short interest raised at 1,099,173 and short average daily volume reached at 192,689. Moreover, percentage of shorted shares reached at 0.07% on October 13.
Evoke Pharma Inc., is a specialty pharmaceutical manufacturer, founded on January 29, 2007. It is focused mainly on the development of drugs for treatment of gastrointestinal (GI) diseases and disorders. It is currently developing EVK-001, a nasal spray to provide relief from symptoms related to recurrent and acute diabetic gastroparesis in women.
Investment firms have updated their shares in this leading gastroparesis drugs market player. According to the statistics at the end of the quarter, Sphera Funds Management Ltd. purchased a total of 71,022 shares, increasing its stakes by 14.2%. The value in dollars reached $1,907,000 from $1,280,000, registering a change of 49.0% since the last quarter.
Wells Fargo & Company/mn sold its 2,043 shares, lowering its stakes by 40.9%. The value in dollars decreased from $13,000 to $10,000, registering a reduction of 23.1% since the last quarter. As per the statistics provided by Morgan Stanley, the company purchased 491 shares, increasing its stake by 5,455.6%. The value of the total investment in the company increased from $0 to $2,000, with gain of $2,000 since the last quarter.
On October 30, FBR & Co kept the company rating of “Buy” and made not change in price target of $10.00. On October 24, HC Wainwright held the “Buy” rating, estimating a price of $9.00.
On October 18, Northland Securities kept the stock rating at “Buy” without changing the current price target of $10.00. On October 6, Seaport Global Securities gave a rating at “Buy”, with a target price of $10.00. On September 18, HC Wainwright kept the stock rating of “Buy”, without changing its current price target of $9.00.
In its recent report on the global gastroparesis drugs market, Big Market Research states that the market was valued at $4,667 million in 2016, and would reach $6,486 million by 2023, growing at a CAGR of 4.7% from 2017 to 2023. The report offers extensive analysis of key market segments, key regions, and major manufacturers to help market players take necessary steps to achieve growth.